O ovoj e-knjizi
This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).
Ocijenite ovu e-knjigu
Recite nam šta mislite.
Informacije o čitanju
Pametni telefoni i tableti
Instalirajte aplikaciju Google Play Knjige za Android i iPad/iPhone uređaje. Aplikacija se automatski sinhronizira s vašim računom i omogućava vam čitanje na mreži ili van nje gdje god da se nalazite.
Laptopi i računari
Audio knjige koje su kupljene na Google Playu možete slušati pomoću web preglednika na vašem računaru.
Elektronički čitači i ostali uređaji
Da čitate na e-ink uređajima kao što su Kobo e-čitači, morat ćete preuzeti fajl i prenijeti ga na uređaj. Pratite detaljne upute Centra za pomoć da prenesete fajlove na podržane e-čitače.
